Vaccination Advances for HBV, HPV, and Influenza
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Vaccines and Public Health".
Deadline for manuscript submissions: 31 August 2025 | Viewed by 136
Special Issue Editor
Interests: health behavior theory innovation and application; health promotion and health equity among vulnerable population; interdisciplinary research of behavioral science and other disciplines
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hepatitis B leads to chronic liver disease and cancer, causing approximately 1.1 million deaths annually. Human papillomavirus (HPV) is responsible for almost all cases of cervical cancer and other malignancies, resulting in over 300,000 deaths each year. With its seasonal and pandemic potential, influenza affects millions globally, leading to substantial morbidity and mortality. Vaccines for these diseases have shown effectiveness: HBV and HPV vaccines offer 90-100% against cancer-causing strains, and influenza vaccines reduce illness and death. High vaccination coverage prevents individual infections and promotes herd immunity. This Special Issue welcomes submissions including but not restricted to the following:
- Progress in HBV, HPV, or influenza vaccination among vulnerable subpopulations (e.g., infants, children, elderly, health care workers, etc);
- Integrated vaccination programs;
- Different vaccination strategies for HBV, HPV, or influenza across regions, particularly new vaccine technologies.
Dr. Wangnan Cao
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HBV
- HPV
- influenza
- vaccination
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
